147 
The institutions themselves might be free to work out, in recognition 
of peculiarly local conditions, the particular mechanisms for compensation. 
It is not simply enough to be safe in a dangerous world, or to try to be 
safe. Where there are going to be injuries, those injuries have to be 
compensated. 
DR. FREDRICKSON: Thank you. Those comments were from Mr. Dan Singer. 
I think that I have time for one more comment. Dr. Shaw? 
DR. SHAW: In followup here, I think that the ripple effect might 
extend to human subjects in any experimentation, and if we are going to 
require informed consent by the institutional review committees for human 
experiments, then I think that we should consider the need for informed 
consent for laboratory workers, for janitors, for secretaries in these 
areas of biohazard, and that this could well be considered in tomorrow's 
discussion of procedures. 
DR. FREDRICKSON: Thank you. Dr. Shaw. 
The last public witness that we will hear today is Dr. Steven 
Wiesenfeld, from the Jewish Hospital in Denver. 
Yes, Dr. Redford? 
DR. REDFORD: I just wanted to add the comment to the discussion we 
were just having, that it seems to me that part of the question really 
raised is not whether we should have peer group committees, but their 
composition. This would be a question for the NIH as to what directives 
it gave the institution with respect to the composition of peer group 
committees. That would be a very important administrative consideration. 
With respect to insurance as an incentive to institutions, I suppose 
that would depend on who was paying for the insurance. In my institution, 
all liability insurance is paid for by a fee collected from the faculty. 
I don't think that would have an effect upon the institution. 
DR. FREDRICKSON: Thank you. 
Dr. Wiesenfeld? 
DR. WIESENFELD: Thank you, Dr. Fredrickson. 
I come before you as a spectator and I hope that my comments are 
helpful to the committee. I represent only myself and no particular 
group. I am a physician at the National Jewish Hospital in Denver, and 
I am trained in internal medicine and immunology, and I spent two years 
at NIH in the slow virus laboratory of Dr. Gajdusek and Dr. Gibbs. 
[288] 
